In The News: Department of Brain Health
The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.
Up to 76% of patients with Alzheimer’s disease experience agitation, including pacing, restlessness and verbal or physical aggression.
The newest of these semi-local developments is the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio diagnostic test, which is the first test of its kind to diagnose Alzheimer's via blood samples. ÐÔÊӽ紫ý's Kirk Kerkorian School of Medicine contributed research to the test, which the FDA approved last year.
Nevada’s aging population is growing and so are diagnoses for brain diseases. 8 News Now spoke with Dr. Samantha John with the ÐÔÊӽ紫ý. She says our state now has one of the fastest-rising rates of neurodegenerative disease.
A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.
The new report, published in the peer-reviewed academic journal Alzheimer’s Research & Therapy, involved medical experts and researchers in dementia from the National Institutes of Health in Baltimore, the Icahn School of Medicine at Mount Sinai in New York, the University of Nevada in Las Vegas, and the Medical University of South Carolina in Charleston, S.C.
GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% reduction in dementia risk.
More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with ÐÔÊӽ紫ý.
More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with ÐÔÊӽ紫ý.
A blood test for Alzheimer’s Disease a game-changer for patients and their families.
A blood test for Alzheimer’s Disease a game-changer for patients and their families.
As current drugs fall short, companies are exploring new targets to treat the neurodegenerative disease